Cost Utility Analysis Based on a Head-to-Head Phase 3 Trial Comparing Ustekinumab and Etanercept in Patients with Moderate-to-Severe Plaque Psoriasis: A Canadian Perspective

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Craig L. Leonardi, Alexa B. Kimball, Kim Papp et al. · The Lancet · 2008 · 1.9K citations

Medicine, Dermatology, Immunology +15

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Kim Papp, Richard G. Langley, Mark Lebwohl et al. · The Lancet · 2008 · 1.4K citations

Medicine, Dermatology, Immunology +15

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

C.E.M. Griffiths, Bruce Strober, Peter van de Kerkhof et al. · New England Journal of Medicine · 2010 · 851 citations

Medicine, Dermatology, Pharmacotherapy +13

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

Richard G. Langley, Steven R. Feldman, Chenglong Han et al. · Journal of the American Academy of Dermatology · 2010 · 216 citations

Medicine, Dermatology, Pharmacotherapy +12

A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis

Angela Moore, Kenneth B. Gordon, Sewon Kang et al. · Journal of the American Academy of Dermatology · 2006 · 156 citations

Medicine, Dermatology, Pharmacotherapy +9